ArticleESMO open2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex-based differences in treatment-related adverse events (TRAEs) have been described across several anticancer therapies. However, sex-disaggregated safety data for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC) is lacking. PATIENTS AND
methodsWe conducted a monocentric cohort study including patients with advanced NSCLC treated with developmental ADCs within phase I-II clinical trials at Gustave Roussy (2018-2023). Clinically significant TRAEs (grade ≥2, Common Terminology Criteria for Adverse Events version 5.0), dose modifications, hospitalisations, and survival outcomes were analysed according to sex using univariate and multivariate analysis.
resultsOur population included 132 patients [women, 64 (48.5%); men, 68 (51.5%)] receiving ADCs targeting TROP2 (32.6%), ITGB6 (31.8%), HER2 (13.6%), CEACAM5 (13.6%), HER3 (5.4%), c-MET (2.3%), and Nectin-4 (0.7%). Overall, 100 (76%) and 39 (29%) patients experienced grade ≥2 and grade ≥3 TRAEs, respectively. Women had a higher incidence of grade ≥2 TRAEs than men [82.8% versus 69.1%; adjusted odds ratio (OR) 2.8, 95% confidence interval (CI) 1.03-7.84, P = 0.04)] and a higher median number of TRAEs (2 versus 1, P = 0.04). Metabolic TRAEs (anorexia, weight loss, ion and lipid imbalances) were significantly more frequent in women (29.7% versus 10.3%; OR 3.68, 95% CI 1.42-9.49, P = 0.009), as were dose reductions (37.5% versus 19.1%; OR 3.35, 95% CI 1.24-9.01, P = 0.02).
conclusionsWomen treated with developmental ADCs for advanced NSCLC experience a higher burden of clinically relevant TRAEs. Our data suggest that sex may represent a key variable to integrate into safety reporting and monitoring strategies for developmental ADCs in NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.